Literature DB >> 31398353

Recent advances in the therapeutic uses of chondroitinase ABC.

E Muir1, F De Winter2, J Verhaagen2, J Fawcett3.   

Abstract

Many studies, using pre-clinical models of SCI, have demonstrated the efficacy of chondroitinase ABC as a treatment for spinal cord injury and this has been confirmed in laboratories worldwide and in several animal models. The aim of this review is report the current state of research in the field and to compare the relative efficacies of these new interventions to improve outcomes in both acute and chronic models of SCI. We also report new methods of chondroitinase delivery and the outcomes of two clinical trials using the enzyme to treat spinal cord injury in dogs and disc herniation in human patients. Recent studies have assessed the outcomes of combining chondroitinase with other strategies known to promote recovery following spinal cord injury and new approaches. Evidence is emerging that one of the most powerful combinations is that of chondroitinase with cell transplants. The particular benefits of each of the different cell types used for these transplant experiments are discussed. Combining chondroitinase with rehabilitation also improves outcomes. Gene therapy is an efficient method of enzyme delivery to the injured spinal cord and circumvents the issue of the enzyme's thermo-instability. Other methods of delivery, such as via nanoparticles or synthetic scaffolds, have shown promise; however, the outcomes from these experiments suggest that these methods of delivery require further optimization to achieve similar levels of efficacy to that obtained by a gene therapy approach. Pre-clinical models have also shown chondroitinase is efficacious in the treatment of other conditions, such as peripheral nerve injury, stroke, coronary reperfusion, Parkinson's disease and certain types of cancer. The wide range of conditions where the benefits of chondroitinase treatment have been demonstrated reflects the complex roles that chondroitin sulphate proteoglycans (its substrate) play in health and disease and warrants the enzyme's further development as a therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cell transplant; Chondroitinase ABC; Combination therapies; Gene therapy; Molecular scaffolds; Neurodegeneration; Peripheral nerve injury; Spinal cord injury

Mesh:

Substances:

Year:  2019        PMID: 31398353     DOI: 10.1016/j.expneurol.2019.113032

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  22 in total

Review 1.  Gene-Modified Stem Cells for Spinal Cord Injury: a Promising Better Alternative Therapy.

Authors:  Yirui Feng; Yu Li; Ping-Ping Shen; Bin Wang
Journal:  Stem Cell Rev Rep       Date:  2022-05-19       Impact factor: 5.739

2.  Chondroitin sulfate proteoglycans prevent immune cell phenotypic conversion and inflammation resolution via TLR4 in rodent models of spinal cord injury.

Authors:  Marina Sánchez-Petidier; Emily R Burnside; Smaranda R Badea; Isaac Francos-Quijorna; Abel Torres-Espin; Lucy Marshall; Fred de Winter; Joost Verhaagen; Victoria Moreno-Manzano; Elizabeth J Bradbury
Journal:  Nat Commun       Date:  2022-05-25       Impact factor: 17.694

3.  Chondroitinase ABC Administration Facilitates Serotonergic Innervation of Motoneurons in Rats With Complete Spinal Cord Transection.

Authors:  Masahito Takiguchi; Kanae Miyashita; Kohei Yamazaki; Kengo Funakoshi
Journal:  Front Integr Neurosci       Date:  2022-06-30

4.  Editorial: Perineuronal Nets as Therapeutic Targets for the Treatment of Neuropsychiatric Disorders.

Authors:  Caroline A Browne; Katherine Conant; Amy W Lasek; Juan Nacher
Journal:  Front Synaptic Neurosci       Date:  2022-06-10

5.  EA Improves the Motor Function in Rats with Spinal Cord Injury by Inhibiting Signal Transduction of Semaphorin3A and Upregulating of the Peripheral Nerve Networks.

Authors:  Rong Hu; Haipeng Xu; Yaheng Jiang; Yi Chen; Kelin He; Lei Wu; XiaoMei Shao; Ruijie Ma
Journal:  Neural Plast       Date:  2020-11-21       Impact factor: 3.599

Review 6.  The Influence of Neuron-Extrinsic Factors and Aging on Injury Progression and Axonal Repair in the Central Nervous System.

Authors:  Theresa C Sutherland; Cédric G Geoffroy
Journal:  Front Cell Dev Biol       Date:  2020-03-25

Review 7.  Emerging and Adjunctive Therapies for Spinal Cord Injury Following Acute Canine Intervertebral Disc Herniation.

Authors:  Melissa J Lewis; Nicolas Granger; Nick D Jeffery
Journal:  Front Vet Sci       Date:  2020-10-15

Review 8.  Aggrecan, the Primary Weight-Bearing Cartilage Proteoglycan, Has Context-Dependent, Cell-Directive Properties in Embryonic Development and Neurogenesis: Aggrecan Glycan Side Chain Modifications Convey Interactive Biodiversity.

Authors:  Anthony J Hayes; James Melrose
Journal:  Biomolecules       Date:  2020-08-27

9.  A Western diet impairs CNS energy homeostasis and recovery after spinal cord injury: Link to astrocyte metabolism.

Authors:  Ha Neui Kim; Monica R Langley; Whitney L Simon; Hyesook Yoon; Laurel Kleppe; Ian R Lanza; Nathan K LeBrasseur; Aleksey Matveyenko; Isobel A Scarisbrick
Journal:  Neurobiol Dis       Date:  2020-05-04       Impact factor: 5.996

Review 10.  Multi-target approaches to CNS repair: olfactory mucosa-derived cells and heparan sulfates.

Authors:  Susan L Lindsay; George A McCanney; Alice G Willison; Susan C Barnett
Journal:  Nat Rev Neurol       Date:  2020-02-25       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.